2022 American Transplant Congress » Kidney Chronic Antibody Mediated Rejection

7:00pm-8:00pm

Antibody-Mediated Allograft Rejection is Associated with an Increase in Peripheral Differentiated Cd28-cd8+ T Cells – Analyses of a Cohort of 1032 Kidney Transplant Recipients

H. L. Mai¹, N. Degauque¹, S. Le Bot¹, M. Rimbert¹, K. Renaudin¹, R. Danger¹, F. Le Borgne², C. Kerleau¹, F. Delbos³, M. Giral¹, S. Brouard¹

7:00pm-8:00pm

Chronic Active Antibody Mediated Rejection: 3 Month Response Rates to Treatment and Predictors of Graft Survival

F. Aziz, M. Jorgenson, S. Parajuli, N. Garg, V. Manchala, E. Yousif, D. Mandelbrot, L. Hidalgo, M. Mohamed, W. Zhong, A. Djamali

7:00pm-8:00pm

Defining New Arterial and Arteriolar Lesions Accompanying Transplant Glomerulopathy: Potential Additions to the Histologic Assessment of ABMR

A. Perkowska-Ptasinska¹, D. Deborska-Materkowska², M. Ciszek³, M. Myslak⁴, J. Chang⁵, J. Reeve⁶, P. Halloran⁷

7:00pm-8:00pm

Gene Expression Profiles of Peritubular Capillarits in Chronic Antibody-Mediated Rejection

M. Eder¹, M. Röbl¹, H. Omic¹, B. Adam², D. Cejka³, N. Kozakowski⁴, D. D´Andrea⁵, M. Mengel², Ž. Kikić⁵

7:00pm-8:00pm

Membrane Attack Complex as a More Sensitive Tool to Evaluate Complement Activation in Kidney Transplant Recipients with Donor-Specific Antibodies

C. Arias-Cabrales, D. Redondo-Pachón, E. Rodríguez, M. Riera, A. Buxeda, M. Pérez-Sáez, C. Burballa, L. Llinas, J. Pascual, M. Crespo

7:00pm-8:00pm

Monitoring Efficacy of Tocilizumab Treatment for Chronic Antibody Mediated Rejection (cAMR) in Kidney Transplants Using Donor-Derived Cell-Free DNA (dd-cf-DNA)

J. Tang¹, A. Vo¹, E. Huang¹, X. Zhang², N. Ammerman¹, A. Peng¹, R. Najjar¹, S. Sethi¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹

7:00pm-8:00pm

Non-HLA Autoantibodies: The Hidden Offenders to Double the Trouble

R. Naik¹, W. Dabbas¹, I. Tang², J. Almario³, Z. Hajjiri¹

7:00pm-8:00pm

Outcomes of Highly-Sensitized, Virtual and Flow Cross-Match Negative Renal Transplant Recipients: A Retrospective Observational Study

A. Agrawal¹, B. Smith¹, M. Gandhi², C. Schinstock¹

7:00pm-8:00pm

Polymorphisms in Ctla-4 Predict De Novo Donor Specific Antibody Formation After Kidney Transplantation

K. Ono, K. Ide, H. Yamane, S. Akimoto, N. Tanimine, H. Tahara, M. Ohira, Y. Tanaka, H. Ohdan

7:00pm-8:00pm

Poor Outcomes in Patients with Transplant Glomerulopathy Independent of Banff Categorization or Therapeutic Interventions

K. Wu¹, D. Schmidt¹, C. Lopez del Moral¹, Q. Zhang¹, F. Halleck¹, M. G. Naik¹, N. Lachmann², B. Rudolph³, K. Budde¹

7:00pm-8:00pm

The Natural History of De Novo DSA After Kidney Transplantation

C. López del Moral¹, N. Lachmann², S. Hergovits², D. Stauch², A. Akifova³, M. Naik³, B. Osmanodja³, D. Schmidt³, K. Budde³

7:00pm-8:00pm

Tocilizumab in Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: A Case Series

B. Boonpheng¹, R. Bakthavatsalam², C. D. Blosser¹, I. C. De Castro¹, I. Gimferrer³, Y. Ng¹, N. Leca¹